Ciprofloxacin

Where the papers sit

12 papers from the last 6 months study ciprofloxacin directly · updated from PubMed 3 Oct 2026

• Antibiotic Development and Delivery

  Antibiotic development is linking controlled delivery, resistance surveillance and safer fluoroquinolone design. Cleavable and keratin hydrogels aim to sustain local treatment for wounds, while efflux-pump profiling defines bacterial responses to ciprofloxacin and amoxicillin. Degradable fluoroquinolones address environmental persistence, and infection models support preclinical testing against Pseudomonas aeruginosa. The set converges on effective therapy with less resistance and ecological burden.

  6 papers · 50%

• DNA Gyrase and SOS Responses

  DNA gyrase inhibition remains the central route to antibacterial activity, spanning ciprofloxacin-induced DNA supercompaction and new candidate compounds. Docking, synthesis and testing against Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa connect structural design with activity across hit strains. The recurring biology is damage to DNA topology and activation of the bacterial SOS response. Work is moving toward compounds that retain gyrase-directed activity while improving antibacterial breadth.

  3 papers · 25%

• Ciprofloxacin Formulation and Delivery

  Ciprofloxacin formulation work is focused on controlling dissolution, particle behavior and site-specific delivery. Thiolated gum ghatti nanoparticles target sustained ocular administration, while small-molecule analogues are used to inhibit precipitation and preserve supersaturation. X-ray diffraction, FTIR, zeta potential, particle size and crystallinity repeatedly define how formulation changes drug performance. The shared goal is more stable, bioavailable delivery rather than new antibacterial mechanisms.

  3 papers · 25%